To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
作者信息
Srinivas Sandy, Iagaru Andrei
机构信息
Division of Medical Oncology, Department of Medicine, Stanford University, Stanford, California; and.
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California
出版信息
J Nucl Med. 2021 Nov;62(11):1487-1488. doi: 10.2967/jnumed.121.263035. Epub 2021 Aug 26.
Abstract
摘要
相似文献
1
To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
J Nucl Med. 2021 Nov;62(11):1487-1488. doi: 10.2967/jnumed.121.263035. Epub 2021 Aug 26.
2
PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.
Semin Nucl Med. 2019 Jul;49(4):302-312. doi: 10.1053/j.semnuclmed.2019.02.008. Epub 2019 Apr 30.
3
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.
Br J Radiol. 2024 Aug 1;97(1160):1391-1404. doi: 10.1093/bjr/tqae092.
4
[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.
Eur J Nucl Med Mol Imaging. 2015 May;42(6):987-8. doi: 10.1007/s00259-014-2978-1. Epub 2015 Jan 9.
5
A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1611-1613. doi: 10.1007/s00259-017-3767-4. Epub 2017 Jul 4.
6
Development of F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior.
Mol Pharm. 2020 Mar 2;17(3):933-943. doi: 10.1021/acs.molpharmaceut.9b01179. Epub 2020 Feb 17.
7
[PSMA-targeted radioligand therapy in prostate cancer].
Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3.
8
[PSMA-based theranostics for prostate cancer : From imaging to treatment].
Urologe A. 2020 May;59(5):617-625. doi: 10.1007/s00120-020-01193-x.
9
Prostate-specific membrane antigen radioligand therapy of prostate cancer.
Q J Nucl Med Mol Imaging. 2019 Mar;63(1):29-36. doi: 10.23736/S1824-4785.19.03155-8. Epub 2019 Jan 15.
10
PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
Radiat Oncol. 2018 May 11;13(1):90. doi: 10.1186/s13014-018-1047-5.
引用本文的文献
1
Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.
Front Cell Dev Biol. 2022 Aug 12;10:958180. doi: 10.3389/fcell.2022.958180. eCollection 2022.
2
Radiolabeled PSMA Inhibitors.
Cancers (Basel). 2021 Dec 13;13(24):6255. doi: 10.3390/cancers13246255.
3
The VISION Forward: Recognition and Implication of PSMA-/F-FDG+ mCRPC.
J Nucl Med. 2022 Jun;63(6):812-815. doi: 10.2967/jnumed.121.263274. Epub 2021 Dec 21.
4
PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
J Nucl Med. 2021 Nov;62(11):1489-1491. doi: 10.2967/jnumed.121.263159.
5
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer.
Cancers (Basel). 2021 Sep 8;13(18):4522. doi: 10.3390/cancers13184522.
本文引用的文献
1
Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
J Nucl Med. 2021 Aug 1;62(8):1025-1026. doi: 10.2967/jnumed.121.262710. Epub 2021 Jun 24.
2
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
3
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
4
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Oncologist. 2021 Feb;26(2):139-146. doi: 10.1002/onco.13585. Epub 2020 Nov 17.
5
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1200-1210. doi: 10.1007/s00259-020-05040-1. Epub 2020 Sep 24.
6
EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.
7
Toward achieving precision health.
Sci Transl Med. 2018 Feb 28;10(430). doi: 10.1126/scitranslmed.aao3612.
8
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.
9
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16.
10
Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29.
Zotero 插件